Rather & Kittrell Inc. Buys Shares of 17,350 Humacyte, Inc. (NASDAQ:HUMA)

Rather & Kittrell Inc. purchased a new position in shares of Humacyte, Inc. (NASDAQ:HUMA) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 17,350 shares of the company’s stock, valued at approximately $88,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp lifted its holdings in Humacyte by 66.1% during the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after acquiring an additional 1,895,529 shares in the last quarter. CenterBook Partners LP bought a new position in shares of Humacyte during the 4th quarter valued at about $6,463,000. Vanguard Group Inc. grew its position in shares of Humacyte by 10.8% in the 4th quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock valued at $28,294,000 after purchasing an additional 543,995 shares during the period. Franklin Resources Inc. bought a new stake in Humacyte during the 4th quarter worth approximately $2,189,000. Finally, Thrivent Financial for Lutherans raised its holdings in Humacyte by 217.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 415,262 shares of the company’s stock worth $2,097,000 after buying an additional 284,368 shares during the period. Institutional investors and hedge funds own 44.71% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Benchmark reiterated a “buy” rating on shares of Humacyte in a report on Thursday, February 27th. HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Humacyte in a research note on Wednesday, March 12th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price objective on shares of Humacyte in a research report on Wednesday, March 26th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Humacyte has a consensus rating of “Buy” and an average price target of $13.71.

Insider Activity at Humacyte

In other Humacyte news, CFO Dale A. Sander purchased 20,000 shares of the stock in a transaction dated Thursday, April 10th. The stock was bought at an average price of $1.53 per share, with a total value of $30,600.00. Following the acquisition, the chief financial officer now owns 40,600 shares of the company’s stock, valued at approximately $62,118. This represents a 97.09 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Kathleen Sebelius acquired 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, April 8th. The stock was bought at an average cost of $1.32 per share, with a total value of $66,000.00. Following the purchase, the director now owns 91,207 shares in the company, valued at $120,393.24. The trade was a 121.34 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 83,993 shares of company stock worth $118,224. Insiders own 11.20% of the company’s stock.

Humacyte Stock Performance

NASDAQ:HUMA opened at $1.54 on Wednesday. The stock’s 50-day simple moving average is $2.76 and its 200 day simple moving average is $4.12. Humacyte, Inc. has a 52-week low of $1.15 and a 52-week high of $9.97. The company has a market cap of $238.88 million, a P/E ratio of -1.15 and a beta of 1.62.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Friday, March 28th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. The company had revenue of $7.23 million for the quarter, compared to the consensus estimate of $0.64 million. As a group, equities analysts predict that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.